Profile data is unavailable for this security.
About the company
Fusion Antibodies PLC, formerly Fusion Antibodies, Ltd., is a United Kingdom-based cancer therapeutics developer. The Company develops and commercializes antibody-based therapeutics for cancer. The Company develops a range of antibody engineering services based around monoclonal antibodies. It focuses in the expression and purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. Its technology generates target specific antibodies from protein antigens. The Company's therapeutic and diagnostic research and development are offered as a service to pharmaceutical, biopharmaceutical and academic researchers.
- Revenue in GBP (TTM)3.90m
- Net income in GBP-697.00k
- Incorporated2000
- Employees47.00
- LocationFusion Antibodies PLCSpringbank Industrial Estate1 Springbank RoadBELFAST BT17 0QLUnited KingdomGBR
- Phone+44 289 043 2800
- Fax+44 289 002 0446
- Websitehttps://fusionantibodies.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Midatech Pharma PLC | 390.00k | -22.14m | 17.03m | 65.00 | -- | 2.33 | -- | 43.67 | -0.8572 | -0.9011 | 0.016 | 0.1158 | 0.0192 | -- | 0.1252 | 6,000.00 | -109.24 | -20.71 | -148.64 | -24.26 | -- | -- | -5,676.67 | -753.63 | -- | -- | 0.4355 | -- | -65.22 | 33.83 | 11.86 | -- | -20.90 | -- |
| Provexis plc | 347.94k | -406.23k | 17.60m | 4.00 | -- | 21.49 | -- | 50.59 | -0.0002 | -0.0002 | 0.0002 | 0.0004 | 0.7476 | 1.28 | 3.49 | -- | -91.21 | -133.18 | -52.06 | -68.32 | 89.72 | -- | -122.00 | -185.86 | 3.06 | -- | 0.00 | -- | 7.99 | 55.54 | 20.82 | -- | -- | -- |
| Skinbiotherapeutics PLC | 0.00 | -1.44m | 24.94m | 4.00 | -- | 6.76 | -- | -- | -0.0113 | -0.0113 | 0.00 | 0.0237 | 0.00 | -- | -- | -- | -45.95 | -- | -48.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -35.96 | -- | -- | -- |
| MiLOC Group Limited | 2.31m | -3.33m | 25.26m | 6.00 | -- | -- | -- | 10.94 | -0.0406 | -0.0406 | 0.0282 | -0.0717 | 1.41 | 2.82 | 13.54 | -- | -211.42 | -140.25 | -- | -- | 34.11 | 41.02 | -149.57 | -218.44 | 0.0898 | -37.67 | -- | -- | 44.65 | 0.9406 | -7.05 | -- | 25.76 | -- |
| Tissue Regenix Group PLC | 13.05m | -5.26m | 28.31m | 99.00 | -- | 0.7634 | -- | 2.17 | -0.0041 | -0.0041 | 0.0098 | 0.0053 | 0.3149 | 1.54 | 4.60 | 131,808.10 | -13.09 | -31.17 | -14.33 | -34.51 | 46.82 | 49.52 | -41.57 | -137.51 | 4.00 | -11.83 | 0.0778 | -- | 12.17 | 164.86 | 14.82 | -- | 41.69 | -- |
| ReNeuron Group Plc | 6.07m | -11.41m | 30.92m | 61.00 | -- | 2.34 | -- | 5.10 | -0.3587 | -0.3587 | 0.1907 | 0.4154 | 0.2338 | -- | 7.93 | 99,426.23 | -43.99 | -31.41 | -60.00 | -35.82 | -- | -- | -188.16 | -1,128.08 | -- | -- | 0.0619 | -- | 12,277.55 | 189.16 | 20.46 | -- | 14.30 | -- |
| Destiny Pharma PLC | 0.00 | -5.04m | 31.72m | 16.00 | -- | 5.52 | -- | -- | -0.1145 | -0.1145 | 0.00 | 0.1224 | 0.00 | -- | -- | 0.00 | -60.16 | -39.10 | -64.38 | -41.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.88 | -- | 92.12 | -- |
| Fusion Antibodies PLC | 3.90m | -697.00k | 31.80m | 47.00 | -- | 5.74 | -- | 8.16 | -0.0316 | -0.0316 | 0.1763 | 0.2178 | 0.6342 | 7.29 | 4.88 | 82,872.34 | -11.35 | -6.71 | -13.28 | -7.75 | 45.49 | 48.38 | -17.89 | -11.41 | 2.49 | -75.64 | 0.0732 | -- | 78.52 | 33.77 | 44.87 | -- | 57.63 | -- |
| Futura Medical plc. | 31.78k | -5.52m | 35.00m | 13.00 | -- | 16.52 | -- | 1,101.38 | -0.0262 | -0.0262 | 0.0001 | 0.0086 | 0.0058 | -- | 10.15 | 2,444.62 | -99.86 | -58.40 | -168.03 | -68.33 | -- | -- | -17,369.76 | -4,623.32 | 3.17 | -- | 0.00 | -- | -- | -6.27 | -51.67 | -- | 33.26 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -1.58m | 40.11m | 7.00 | -- | 20.49 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0045 | 0.00 | -- | -- | 0.00 | -58.29 | -- | -61.72 | -- | -- | -- | -- | -- | -- | -58.81 | 0.4731 | -- | -- | -- | 6.07 | -- | -- | -- |
| Science in Sport PLC | 50.57m | -5.62m | 41.88m | 142.00 | -- | 0.8424 | -- | 0.8281 | -0.0458 | -0.0458 | 0.4121 | 0.368 | 0.849 | 4.28 | 5.09 | -- | -9.43 | -13.25 | -11.15 | -15.48 | 43.91 | 51.63 | -11.11 | -17.63 | 1.57 | -232.00 | 0.0233 | -- | 137.23 | -- | 4.37 | -- | -- | -- |
| OptiBiotix Health PLC | 1.34m | -1.51m | 45.73m | 10.00 | -- | 8.20 | -- | 34.10 | -0.0176 | -0.0176 | 0.0156 | 0.0634 | 0.1814 | 6.42 | 5.68 | 134,088.00 | -20.38 | -14.81 | -21.36 | -15.59 | 46.82 | 64.52 | -112.34 | -266.91 | 4.98 | -- | 0.1178 | -- | 44.84 | -- | -10.32 | -- | 252.06 | -- |
Data as of Nov 23 2020. Currency figures normalised to Fusion Antibodies PLC's reporting currency: UK Pound GBX
15.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Octopus Investments Ltd.as of 14 Aug 2020 | 1.53m | 6.00% |
| Canaccord Genuity Wealth Ltd.as of 21 Sep 2020 | 1.27m | 4.99% |
| Unicorn Asset Management Ltd.as of 14 Aug 2020 | 1.22m | 4.79% |
Data from 31 Jul 2020 - 31 Oct 2020Source: FactSet Research Systems Inc.
